The Role of MAO-B Inhibitors in the Treatment of Parkinson’s Disease

Parkinson's Disease

Volumn , Issue , 2004, Pages 691-704

  Bertoni, John ^a   Elmer, Lawrence ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 56749085287     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9780203508596-64     Document Type: Chapter

References (109)

1. Knoll, J., The pharmacology of selegiline ((-)deprenyl), New aspects, Acta Neurol. Scand., Suppl., 126:83–91, 1989.
2. Lees, A. J., Comparison of therapeutic effects and mor-tality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s dis-ease. Parkinson’s Disease Research Group of the United Kingdom, B. M. J., 311(7020):1602–7, Dec. 16, 1995.
3. Knoll, J., Deprenyl (selegiline): The history of its devel-opment and pharmacological action, Acta Neurol. Scand., Suppl., 95:57–80, 1983.
4. Zeller, E. A., Barsky, J., Fouts, J. E., Kirchheimer, W. F., Van Orden, I. S., Influence of isonicotinic acid hydrazide (INH) and 1-isonicotinic-2isopropyl hydrazide (IIH) on bacterial and mammalian enzymes, Experientia., 8:349–350, 1952.
5. Blackwell, B., Hypertensive crisis due to monoamine oxidase inhibitors, Lancet, 11:849–851, 1963.
6. Horwitz, D., Lovenberg, W., Engelmann, K., Sjoerdsma, A., Monoamine oxidase inhibitors, tyramine and cheese, JAMA, 188:1108–1110, 1964.
7. Knoll, J., Ecseri, Z., Kelemen, K., Nievel, J., Knoll, B., Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer, Arch Int. Pharmacodyn. Ther., 155(1):154–64, May, 1965.
8. Johnston, J. P., Some observations upon a new inhibitor of monoamine oxidase in brain tissue, Biochem. Phar-macol., 17(7):1285–97, July, 1968.
9. Riederer, P., Jellinger, K., Danielczyk, W., Seemann, D., Ulm, G., Reynolds, G. P., Birkmayer, W., Koppel, H., Combination treatment with selective monoamine oxi-dase inhibitors and dopaminergic agonists in Parkin-son’s disease: Biochemical and clinical observations, Adv., Neurol., 37:159–76, 1983.
10. Ehringer, H. Hornykiewicz, Verteilung von noradrenalin und dopamine (3-hydroxytyramin) im gehirn des men-schen und ihr verhalten bei erkrankungen des extrapy-ramidalen systems, Klin Wschr., 38:1236–1239, 1960.
11. Rinne, U. K., Recent advances in research on Parkin-sonism, Acta Neurol. Scand., Suppl., 67:77–113, 1978.
12. Mann, J., Gershon, S., L-deprenyl, a selective monoam-ine oxidase type-B inhibitor in endogenous depression, Life Sci., 17;26(11):877–82, March, 1980.
13. Glover, V., Sandler, M., Owen, F., Riley, G. J., Dopamine is a monoamine oxidase B substrate in man, Nature, 6;265(5589):80–1, January 6, 1977.
14. Heinonen, E. H., Myllyla, V., Sotaniemi, K., Lamin-tausta, R., Salonen, J. S., Anttila, M., Savijarvi, M., Kotila, M., Rinne, U. K., Pharmacokinetics and metab-olism of selegiline, Acta Neurol. Scand., Suppl., 126:93–9, 1989.
15. Heinonen, E. H., Rinne, U. K., Selegiline in the treat-ment of Parkinson’s disease, Acta Neurol. Scand., Suppl., 126:103–11, 1989.
16. Fowler, J. S., MacGregor, R. R., Wolf, A. P., Arnett, C. D., Dewey, S. L., Schlyer, D., Christman, D., Logan, J., Smith, M., Sachs, H. et al., Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET, Science, 3;235(4787):481–5, Jan-uary 3, 1987.
17. Fowler, J. S., Wolf, A. P., MacGregor, R. R., Dewey, S. L., Logan, J., Schlyer, D. J., Langstrom, B., Mechanis-tic positron emission tomography studies: Demonstra-tion of a deuterium isotope effect in the monoamine oxidase-catalyzed binding of [11C]L-deprenyl in living baboon brain, J. Neurochem., 51(5):1524–34, Novem-ber, 1988.
18. Riederer, P., Youdim, M. B., Rausch, W. D., Birkmayer, W., Jellinger, K., Seemann, D., On the mode of action of L-deprenyl in the human central nervous system, J. Neural. Transm., 43(3-4):217–26, 1978.
19. Riederer, P., Youdim, M. B., Birkmayer, W., Jellinger, K., Monoamine oxidase activity during (–)-deprenil therapy: Human brain post-mortem studies, Adv. Bio-chem. Psychopharmacol., 19:377–82, 1978.
20. Reiderer, P., Reynolds, G. P., Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons’s disease, Br. J. Clin. Pharmacol., Jan., 9(1): 98–9, 1980.
21. Riederer, P., Youdim, M. B., Monoamine oxidase activ-ity and monoamine metabolism in brains of parkinso-nian patients treated with l-deprenyl, J. Neurochem., 46(5):1359–65, May, 1986.
22. Glover, V., Elsworth, J. D., Sandler, M., Dopamine oxi-dation and its inhibition by (-)-deprenyl in man, J. Neu-ral. Transm., Suppl., (16):163–72, 1980.
23. Reynolds, G. P., Elsworth, J. D., Blau, K., Sandler, M., Lees, A. J., Stern, G. M., Deprenyl is metabolized to methamphetamine and amphetamine in man, Br. J. Clin. Pharmacol., 6(6):542–4, December, 1978.
24. Yoshida, T., Yamada, Y., Yamamoto, T., Kuroiwa, Y., Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: Relationship of metabolism to MAO-B inhibitory potency, Xenobiotica,16(2):129–36, February, 1986.
25. Parkinson, D., Callingham, B. A., Substrate and inhib-itor selectivity of human heart monoamine oxidase, Bio-chem. Pharmacol., 15;28(10):1639–43, 1979.
26. Egashira, T., Yamamoto, T., Yamanaka, Y., Effects of d-methamphetamine on monkey brain monoamine oxi-dase, in vivo and in vitro, Jpn. J. Pharmacol., 45(1): 79–88, 1987.
27. Mytilineou, C., Cohen, G., Deprenyl protects dopamine neurons from the neurotoxic effect of1-methyl-4-phe-nylpyridinium ion, J. Neurochem., 45(6):1951–3, December 1985.
28. Lewin, R., Drug trial for Parkinson’s, Science, 12;236 (4807):1420, June 12, 1987.
29. Fuller, R. W., Hemrick-Luecke, S. K., Perry, K. W., Deprenyl antagonizes acute lethality of1-methyl-4-phe-nyl-1,2,3,6-tetrahydropyridine in mice, J. Pharmacol. Exp. Ther., 247(2):531–5, 1988.
30. Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., Kopin, I. J., Chronic parkinsonism secondary to intravenous injection of meperidine analogues, Psychiatry Res., 1:249–254, 1979.
31. Langston, J. W., Ballard, P. A., Tetrud, J. W., Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis, Science, 219:979–980, 1983.
32. Chiba, K., Trevor, A., Castagnoli, N. Jr., Active uptake of MPP+ a metabolite of MPTP by brain synapto-somes, Biochem. Biophys. Res. Commun., 120: 574–578, 1984.
33. Heikkila, R. E., Manzino, L., Cabbat, F. S., Duvoisin, R. C., Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors, Nature, 311:467–469, 1984.
34. Olanow, C. W., Deprenyl in the treatment of Parkinson’s disease: Clinical effects and speculations on mechanism of action, J. Neural. Transm., Suppl., 48:75–84, 1996.
35. Ebadi, M., Sharma, S., Shavali, S., El Refaey, H., Neu-roprotective actions of selegiline, J. Neurosci. Res., 67(3):285–9, February 1, 2002.
36. Varga, E., Tringer, L., Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopro-pyl-methylpropinyl-HCl, “E-250”), Acta Med. Acad. Sci. Hung., 23(3):289–95, 1967.
37. Mann, J. J., Aarons, S. F., Wilner, P. J., Keilp, J. G., Sweeney, J. A., Pearlstein, T., Frances, A. J., Kocsis, J. H., Brown, R. P., A controlled study of the antidepres-sant efficacy and side effects of(-)-deprenyl. A selective monoamine oxidase inhibitor, Arch Gen. Psychiatry, 46(1):45–50, 1989.
38. Birkmayer, W., Hornykiewicz, O., Der L 3,4-dihydrox-yphenylalanin (DOPA) effect bei der Parkinsonakinese, Wien, Klin. Wochenschr., 73:787–788, 1961.
39. Gerstenbrand, F., Prosenz, P., On the treatment of Par-kinson’s syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa, Praxis, 18, 54(46):1373–7, November 18, 1965.
40. Birkmayer, W., Danielczyk, W., Neumayer, E., Riederer, P., Dopaminergic supersensitivity in parkinsonism, Adv. Neurol., 9:121–129, 1975.
41. Birkmayer, W., Riederer, P., Youdim, M. B., Linauer, W., The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil, J. Neural. Transm., 36(3-4):303–326, 1975.
42. Birkmayer, W., Riederer, P., Ambrozi, L., Youdim, M. B., Implications of combined treatment with “Madopar” and L-deprenil in Parkinson’s disease. A long-term study, Lancet, 1(8009):439–43, February 26, 1977.
43. Csanda, E., Antal J., Antony, M., Csanaky, A., Experi-ences with L-deprenyl in Parkinsonism, J. Neural. Transm., 43(3–4):263–9, 1978.
44. Birkmayer, W., Deprenyl (selegiline) in the treatment of Parkinson’s disease, Acta Neurol. Scand., Suppl., 95:103–5, 1983.
45. Rinne, U. K., Deprenyl (selegiline) in the treatment of Parkinson’s disease, Acta Neurol. Scand., Suppl., 95:107–11, 1983.
46. Gerstenbrand, F., Ransmayr, G., Poewe, W., Deprenyl (selegiline) in combination treatment of Parkinson’s dis-ease, Acta Neurol. Scand., Suppl., 95:123–6, 1983.
47. Lees, A. J., Shaw, K. M., Kohout, L. J., Stern, G. M., Elsworth, J. D., Sandler, M., Youdim, M. B., Deprenyl in Parkinson’s disease, Lancet, 2(8042):791–5, October 15, 1977.
48. Stern, G. M., Lees, A. J., Sandler, M., Recent observa-tions on the clinical pharmacology of (-) deprenyl, J. Neural. Transm., 43(3–4):245–51, 1978.
49. Schachter, M., Marsden, C. D., Parkes, J. D., Jenner, P., Testa, B., Deprenyl in the management of response fluc-tuations in patients with Parkinson’s disease on levodopa, J. Neurol. Neurosurg. Psychiatry, 43(11): 1016–21, 1980.
50. Goldstein, L., The “on-off” phenomena in Parkinson’s disease—treatment and theoretical considerations, Mt. Sinai J. Med., 47(1):80–4, 1980.
51. Eisler, T., Teravainen, H., Nelson, R., Krebs, H., Weise, V., Lake, C. R., Ebert, M. H., Whetzel, N., Murphy, D. L., Kopin, I. J., Calne, D. B., Deprenyl in Parkinson disease, Neurology, 31(1):19–23, 1981.
52. Presthus, J., Hajba, A., Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treat-ment of Parkinson’s disease, Acta Neurol. Scand., Suppl., 95:127–33, 1983.
53. Brodersen, P., Philbert, A., Gulliksen, G., Stigard, A., The effect of L-Deprenyl on on-off phenomena in Par-kinson’s disease, Acta Neurol. Scand., 71(6):494–7, 1985.
54. Fischer, P. A., Baas, H., Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism, J. Neural. Transm., Suppl., 25:137–47, 1987.
55. Golbe, L. I., Duvoisin, R. C., Double-blind trial of R-(-)-deprenyl for the “on-off” effect complicating Par-kinson’s disease, J. Neural. Transm., Suppl., 25:123–9, 1987.
56. Lieberman, A. N., Gopinathan, G., Neophytides, A., Foo, S. H., Deprenyl versus placebo in Parkinson dis-ease: A double-blind study, N. Y. State J. Med., 87(12): 646–9, 1987.
57. Rascol, O., Montastruc, J. L., Senard, J. M., Demonet, J. F., Simonetta, M., Rascol, A., Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in Parkinsonian patients: A double-blind cross-over placebo-controlled trial, Neurology, 38(9): 1387–91, 1988.
58. Heinonen, E. H., Rinne, U. K., Tuominen, J., Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treat-ment, Acta Neurol. Scand., Suppl., 126:113–8, 1989.
59. Teychenne, P. F., Parker, S., Double-blind, crossover placebo controlled trial of selegiline in Parkinson’s dis-ease—an interim analysis, Acta Neurol. Scand., Suppl., 126:119–25, 1989.
60. Sivertsen, B., Dupont, E., Mikkelsen, B., Mogensen, P., Rasmussen, C., Boesen, F., Heinonen, E., Selegiline and levodopa in early or moderately advanced Parkinson’s disease: A double-blind controlled short-and long-term study, Acta Neurol. Scand., Suppl., 126:147–52, 1989.
61. C. D., Chouza, C., Aljanati, R., Scaramelli, A., De Medina, O., Caamano, J. L., Buzo, R., Fernandez, A., Romero, S., Combination of selegiline and controlled release levodopa in the treatment of fluctuations of clin-ical disability in parkinsonian patients, Acta Neurol. Scand., Suppl., 126:127–37, 1989.
62. Golbe, L. I., Deprenyl as symptomatic therapy in Par-kinson’s disease, Clin. Neuropharmacol., 11(5): 387–400, 1988.
63. The Parkinson Study Group, Effect of deprenyl on the progression of disability in early Parkinson’s disease, N. Engl. J. Med., 321(20):1364–71, November 16, 1989.
64. Parkinson Study Group, DATATOP: A multicenter con-trolled clinical trial in early Parkinson’s disease, Arch Neurol., 46(10):1052–60, 1989.
65. Tetrud, J. W., Langston, J. W., The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease, Science, 245(4917):519–22, August 4, 1989.
66. Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A., Hei-nonen, E. H., Selegiline as a primary treatment of Par-kinson’s disease, Acta Neurol. Scand., Suppl., 136:70–2, 1991.
67. Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A., Hei-nonen, E. H., Selegiline as initial treatment in de novo parkinsonian patients, Neurology, 42(2):339–43, 1992.
68. Olanow, C. W., Hauser, R. A., Gauger, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., Esterlitz, J., The effect of deprenyl and levodopa on the progression of Parkinson’s disease, Ann. Neurol., 38(5):771–7, 1995.
69. LeWitt, P. A., Deprenyl’s effect at slowing progression of parkinsonian disability: The DATATOP study. The Parkinson Study Group, Acta Neurol. Scand., Suppl., 136:79–86, 1991.
70. Shoulson, I., An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson’s disease, The Parkinson Study Group, Eur. Neurol., 32 Suppl. 1:46–53, 1992.
71. Schulzer, M., Mak, E., Calne, D. B., The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic, Ann. Neurol., 32(6):795–8, 1992.
72. Brannan, T., Yahr, M. D., Comparative study of sele-giline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson’s disease, Ann. Neu-rol., 37(1):95–8, January, 1995.
73. Olanow, C. W., Mytilineou, C., Tatton, W., Current sta-tus of selegiline as a neuroprotective agent in Parkin-son’s disease, Mov. Disord., 13 Suppl., 1:55–8, 1998.
74. Giladi, N., McDermott, M. P., Fahn, S., Przedborski, S., Jankovic, J., Stern, M., Tanner, C., Freezing of gait in PD: Prospective assessment in the DATATOP cohort, Neurology, 56(12):1712–21, June 26, 2001.
75. Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, J. W., LeWitt, P., Olanow, C. W., Penney, J. B., Tanner, C., Kieburtz, K., Rudolph, A., Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial, Ann. Neurol., 51(5):604–12, 2002.
76. Palhagen, S., Heinonen, E. H., Hagglund, J., Kaugesaar, T., Kontants, H., Maki-Ikola, O., Palm, R., Turunen, J., Selegiline delays the onset of disability in de novo par-kinsonian patients, Swedish Parkinson Study Group, Neurology, 51(2):520–5, 1998.
77. Lees, A. J., Comparison of therapeutic effects and mor-tality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s dis-ease, Parkinson’s Disease Research Group of the United Kingdom, B. M. J., 16;311(7020):1602–7, 1995.
78. Olanow, C. W., Myllyla, V. V., Sotaniemi, K. A., Larsen, J. P., Palhagen, S., Przuntek, H., Heinonen, E. H., Kilkku, O., Lammintausta, R., Maki-Ikola, O., Rinne, U. K., Effect of selegiline on mortality in patients with Parkinson’s disease: A meta-analysis, Neurology, 51(3):825–30, 1998.
79. Lees, A. J., Head, J., Shlomo, Y. B., Selegiline and mortality in Parkinson’s disease: Another view, Ann. Neurol., 41(2):282–3, 1997.
80. Parkinson Study Group, Mortality in DATATOP: A mul-ticenter trial in early Parkinson’s disease, Ann. Neurol., 43(3):318–25, 1998.
81. Oakes, D., Selegiline and excess mortality, Clin. Neu-ropharmacol., 20(6):542, 1997.
82. Ben-Shlomo, Y., Churchyard, A., Head, J., Hurwitz, B., Overstall, P., Ockelford, J., Lees, A. J., Investigation by Parkinson’s Disease Research Group of United King-dom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Par-kinson’s disease: Further results of randomized trial and confidential inquiry, B. M. J.;316(7139):1191–6, 1998
83. Donnan, P. T., Steinke, D. T., Stubbings, C., Davey, P. G., MacDonald, T. M., Selegiline and mortality in sub-jects with Parkinson’s disease: A longitudinal commu-nity study, Neurology, 55(12):1785–9, December 26, 2000.
84. Lees, A. J., Katzenschlager, R., Head, J., Ben-Shlomo, Y., Ten-year follow-up of three different initial treat-ments in de-novo PD: A randomized trial, Neurology, 13;57(9):1687–94, November, 2001.
85. Myllyl, V. V., Sotaniemi, K. A., Hakulinen, P., Maki-Ikol, O., Heinonen, E. H., Selegiline as the primary treatment of Parkinson’s disease—a long-term double-blind study, Acta Neurol. Scand., 95:211–218, 1997.
86. Przuntek, H., Conrad, B., Dichgans, J., Kraus, P. H., Krauseneck, P., Pergande, G., Rinne, U., Schimrigk, K., Schnitker, J., Vogel, H. P., SELEDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa, Eur. J. Neurol., 6(2):141–50, 1999.
87. Wilcock, G. K., Birks, J., Whitehead, A., Evans, S. J., The effect of selegiline in the treatment of people with Alzheimer’s disease: A meta-analysis of published tri-als, Int. J. Geriatr. Psychiatry, 17(2):175–83, 2002.
88. Roselaar, S. E., Langdon, N., Lock, C. B., Jenner P., Parkes, J. D., Selegiline in narcolepsy, Sleep, 10(5): 491–5, 1987.
89. Grewal, M., Hawa, R., Shapiro, C., Treatment of peri-odic limb movements in sleep with selegiline HCl, Mov. Disord., 17(2):398–401, 2002.
90. Houtsmuller, E. J., Thornton, J. A., Stitzer, M. L., Effects of selegiline (l-deprenyl) during smoking and short-term abstinence, Psychopharmacology, (Berl.), 163(2): 213–20, 2002.
91. Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., Bava, A., Effects of selegiline on fronto-temporal dementia: A neuropsychological evaluation, Int. J. Geri-atr. Psychiatry, 17(4):391–2, 2002.
92. Jankovic, J. J., Therapeutic strategies in Parkinson’s dis-ease, in Jankovic, J. J., Tolosa, E., Eds., Parkinson’s disease and Movement Disorders, 4th ed., Lippincott, Philadelphia, P. A., 2002.
93. LeWitt, P., Therapies to extend duration of levodopa action, in Koller, W. C., Paulson, G., Eds., Therapy of Parkinson’s Disease, 2nd ed., Marcel Dekker, New York, 77–90, 1995.
94. Olanow, C. W., Watts, R. L., Koller, W. C., An algorithm (decision tree) for the management of Parkinson’s dis-ease (2001): Treatment guidelines, Neurology, 56(11 Suppl., 5):S1–S88, June, 2001.
95. Waters, C. H., Sethi, K. D., Hauser, R. A., Molho, E., Bertoni, J. M., Zydis selegiline reduces “off” time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study (sub-mitted). 96. Longer-term Zydis selegiline study.
96. Youdim, M. B. H., Gross, A., Finberg, J. P. M., Rasa-giline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B, British Journal of Pharmacology, 132:500–506, 2001.
97. Speiser, Z., Levy, R., Cohen, S., Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders, J. Neural. Transm., Suppl., 52:287–300, 1998.
98. Rabey, J. M., Huberman, S. M., Melamed, E., Korczyn, A., Giladi, N., Inzelberg, R., Djaldetti, R., Klein, C., Berecz, G., Rasagiline mesylate, a new mao-B inhibitor for the treatment of Parkinson’s disease: A double-blind study as adjunctive therapy to levodopa, Clinical Neu-ropharmacology, 23(6):324–330, 2000.
99. Youdim, M. B. H. and Weinstock, M., Novel neuropro-tective anti-Alzheimer drugs with anti-depressant activ-ity derived from the anti-parkinson drug, rasagiline, Mech. Ageing Dev., 123(8):1081–6, April 30, 2002.
100. Youdim, M. B., Wadia, A., Tatton, W., Weinstock, M., The anti-parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo, Ann. NY Acad. Sci., 939:450–8, June, 2001.
101. Akao, Y., Maruyama, W., Shimizu, S., Yi, H., Nakagawa, Y., Shamoto-Nagai, M., Youdim, M. B., Tsujimoto, Y., Naoi, M., Mitochondrial permeability transition medi-ates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan, J. Neuro-chem., 82(4):913–23, 2002.
102. Akao, Y., Maruyama, W., Yi, H., Shamoto-Nagai, M., Youdim, M. B., Naoi, M., An anti-parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells, Neurosci. Lett., 326(2):105–8, June 28, 2002.
103. Maruyama, W., Akao, Y., Youdim, M. B. H., Davis, B. A., Naoi, M., Transfection-enforced Bcl-2 overexpres-sion and an anti-parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl®salsolinol, Journal of Neuro-chemistry, 78:727–735, 2001.
104. Eliash, S., Speiser, Z., Cohen, S., Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats, J. Neural. Transm., 108(8–9):909–23, 2001.
105. Marek, K., Friedman, J., Hauser, R., Juncos, J., LeWitt, P., Miyawaki, E., Tarsy, D., Olanow, C. W., Stern, M., Levy, R., Mulcahy, W., Phase II evaluation for rasagiline mesylate (TVP-1012), a novel anti-parkinsonian drug, in Parkinsonian patients not using levodopa/carbidopa, Presented at the PSG/MDS 11th Annual Symposium, Movement Disorders,12(5):838, 1997.
106. Parkinson Study Group, A controlled trial of rasagiline in early Parkinson’s disease, The Tempo Study, Arch Neurol., 59:1937–1943, December, 2002.
107. Tyramine challenge subgroup of Tempo study, in prep-aration.
108. Rascol, O., Brooks, D., Melamed, E., Oertel, W., Poewe, W., Stocchi, F., Tolosa, E., A comparative randomized study of rasagiline versus placebo or entacapone as adjunct to levodopa in Parkinson’s disease (PD) patients with motor fluctuations, LARGO Manuscript, LARGO Study Group, Abstract.
109. Parkinson Study Group, A controlled trial of rasagiline in Parkinson’s disease patients with levodopa-related motor fluctuations (Presto Study), American Neurolog-ical Association 128th Annual Meeting and the 6th Annual Neurology Outcomes Symposium, San Fran-cisco, CA, October, 19–22, 2003.